PLANTATION, Fla., July 31 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company has filed a registration
statement on Form S-1 with the Securities and Exchange Commission (SEC) for
a secondary offering of Units, each Unit consisting of one share of common
stock and one common stock purchase warrant.
Dawson James Securities, Inc. will act as the lead underwriter for the
offering. A written preliminary prospectus for the offering, when
available, may be obtained directly from: Dawson James Securities,
Prospectus Department, 925 South Federal Highway, Boca Raton, FL 33432,
Phone: (561) 391-5555.
A registration statement relating to these securities being offered has
been filed with the SEC but has not yet become effective. These securities
may not be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy nor shall
there be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, Viragen
is a biotechnology company engaged in the research, development,
manufacture and commercialization of pharmaceutical proteins for the
treatment of cancers and select viral diseases. Our product portfolio
includes: Multiferon(R) (multi- subtype, human alpha interferon) targeting
a range of cancers and select infectious diseases; and humanized monoclonal
antibodies targeting specific antigens over-expressed on many types of
cancers. We are also pioneering research on Avian Transgenic Technology,
with the renowned Roslin Institute, as a revolutionary manufacturing
platform for the large-scale, efficient and economical production of human
therapeutic proteins and antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general.
Forward-looking statements speak only as to the date they are made. The
Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
